Cyclosporin-induced dyslipoproteinemia is associated with selective activation of SREBP-2

American Journal of Physiology - Endocrinology and Metabolism

Volumn 277, Issue 6 40-6, 1999, Pages

  Jinmei, Wu ^a   Zhu, Yong Hong ^a   Patel, Shailendra B ^a  

^a MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

Author keywords

Heart disease; Immunotherapy; Liver; Sterol regulatory element binding protein; Transcription; Very low density lipoprotein

Indexed keywords

APOLIPOPROTEIN B; CHOLESTEROL; CYCLOSPORIN A; LIPID; STEROL REGULATORY ELEMENT BINDING PROTEIN; TRANSCRIPTION FACTOR; TRIACYLGLYCEROL; VERY LOW DENSITY LIPOPROTEIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; ATHEROSCLEROSIS; CONTROLLED STUDY; DRUG INDUCED DISEASE; DRUG MECHANISM; DYSLIPOPROTEINEMIA; FEMALE; GRAFT REJECTION; HYPERTENSION; LIPID METABOLISM; MOUSE; NEPHROTOXICITY; NONHUMAN; ORGAN TRANSPLANTATION; PRIORITY JOURNAL; PROTEIN EXPRESSION;

EID: 4243407045     PISSN: 01931849     EISSN: None     Source Type: Journal    
DOI: 10.1152/ajpendo.1999.277.6.e1087     Document Type: Article

References (43)

1. Al Rayyes, O., A. Wallmark, and C. H. Floren. Additive inhibitory effect of hydrocortisone and cyclosporine on low-density lipoprotein receptor activity in cultured HepG2 cells. Hepatology 26: 967-971, 1997.
2. Ballantyne, C. M., E. J. Podet, W. P. Patsch, Y. Harati, V. Appel, A. M. Gotto, Jr., and J. B. Young. Effects of cyclosporine therapy on plasma lipoprotein levels. JAMA 262: 53-56, 1989.
3. Boss, V., K. L. Abbott, X. F. Wang, G. K. Pavlath, and T. J. Murphy. The cyclosporin A-sensitive nuclear factor of activated T cells (NFAT) proteins are expressed in vascular smooth muscle cells. Differential localization of NFAT isoforms and induction of NFAT-mediated transcription by phospholipase C-coupled cell surface receptors. J. Biol. Chem. 273: 19664-19671, 1998.
4. Brown, M. S., and J. L. Goldstein. The SREBP pathway: regulation of cholesterol metabolism by proteolysis of a membrane-bound transcription factor. Cell 89: 331-340, 1997.
5. Brown, M. S., and J. L. Goldstein. Sterol regulatory element binding proteins (SREBPs): controllers of lipid synthesis and cellular uptake. Nutr. Rev. 56: S1-S3 and S54-S75, 1998.
6. Chan, L. RNA editing: exploring one mode with apolipoprotein B mRNA. Bioessays 15: 33-41, 1993.
7. Dahlback-Sjoberg, H., I. Bjorkhem, and H. M. Princen. Selective inhibition of mitochondrial 27-hydroxylation of bile acid intermediates and 25-hydroxylation of vitamin D3 by cyclosporin A. Biochem. J. 293: 203-206, 1993.
8. Emeson, E. E., and M. L. Shen. Accelerated atherosclerosis in hyperlipidemic C57BL/6 mice treated with cyclosporin A. Am. J. Pathol. 142: 1906-1915, 1993.
9. Ettinger, W. H., W. L. Bender, A. P. Goldberg, and W. R. Hazzard. Lipoprotein lipid abnormalities in healthy renal transplant recipients: persistence of low HDL2 cholesterol. Nephron 47: 17-21, 1987.
10. Fernandez-Miranda, C., C. Guijarro, A. de la Calle, C. Loinaz, I. Gonzalez-Pinto, T. Gornez-Izquierdo, S. Larumbe, E. Moreno, and A. del Palacio. Lipid abnormalities in stable liver transplant recipients - effects of cyclosporin, tacrolimus, and steroids. Transpl. Int. 11: 137-142, 1998.
11. Gordon, D. A. Recent advances in elucidating the role of the microsomal triglyceride transfer protein in apolipoprotein B lipoprotein assembly. Curr. Opin. Lipidol. 8: 131-137, 1997.
12. Greeve, J., I. Altkemper, J. H. Dieterich, H. Greten, and E. Windler. Apolipoprotein B mRNA editing in 12 different mammalian species: hepatic expression is reflected in low concentrations of apoB-containing plasma lipoproteins. J. Lipid Res. 34: 1367-1383, 1993.
13. Harris, K. P., G. I. Russell, S. D. Parvin, P. S. Veitch, and J. Walls. Alterations in lipid and carbohydrate metabolism attributable to cyclosporin A in renal transplant recipients. Br. Med. J. 292: 16, 1986.
14. Hess, M. L., A. Hastillo, T. Mohanakumar, M. J. Cowley, G. Vetrovac, S. Szentpetery, T. C. Wolfgang, and R. R. Lower. Accelerated atherosclerosis in cardiac transplantation: role of cytotoxic B-cell antibodies and hyperlipidemia. Circulation 68: 1194-1101, 1983.
15. Horton, J. D., H. Shimano, R. L. Hamilton, M. S. Brown., and J. L. Goldstein. Disruption of LDL receptor gene in transgenic SREBP-1a mice unmasks hyperlipidemia resulting from production of lipid-rich VLDL. J. Clin. Invest. 103: 1067-1076, 1999.
16. Horton, J. D., I. Shimomura, M. S. Brown, R. E. Hammer, J. L. Goldstein, and H. Shimano. Activation of cholesterol synthesis in preference to fatty acid synthesis in liver and adipose tissue of transgenic mice overproducing sterol regulatory element-binding protein-2. J. Ciln. Invest. 101: 2331-2339, 1998.
17. Kahan, B. D. Cyclosporine. N. Engl. J. Med. 321: 1725-1738, 1989.
18. Kahan, B. D. Cyclosporine: the base for immunosuppressive therapy - present and future. Transplant. Proc. 25: 508-510, 1993.
19. Kasiske, B. L. Risk factors for accelerated atherosclerosis in renal transplant recipients. Am. J. Med. 84: 985-992, 1988.
20. Klee, C. B., H. Ren, and X. Wang. Regulation of the calmodulin-stimulated protein phosphatase, calcineurin. J. Biol. Chem. 273: 13367-13370, 1998.
21. Levy, J., K. Budai, and N. B. Javitt. Bile acid synthesis in HepG2 cells: effect of cyclosporin. J. Lipid Res. 35: 1795-1800, 1994.
22. Li, X., F. Catalina, S. M. Grundy, and S. Patel. Method to measure apolipoprotein B-48 and B-100 secretion rates in an individual mouse: evidence for a very rapid turnover of VLDL and preferential removal of B-48-relative to B-100-containing lipoproteins. J. Lipid Res. 37: 210-220, 1996.
23. Li, X., S. M. Grundy, and S. B. Patel. Obesity in db and ob animals leads to impaired hepatic very low density lipoprotein secretion and differential secretion of apolipoprotein B-48 and B-100. J. Lipid Res. 38: 1277-1288, 1997.
24. Lopez-Miranda, J., E. Vilella, F. Perez-Jimenez, A. Espino, J. A. Jimenez-Pereperez, L. Masana, and P. R. Turner. Low-density lipoprotein metabolism in rats treated with cyclosporine. Metabolism 42: 678-683, 1993.
25. Luke, D. R., J. E. Beck, K. Vadiei, M. Yousefpour, C. F. LeMaistre, and J. C. Yau. Longitudinal study of cyclosporine and lipids in patients undergoing bone marrow transplantation. J. Clin. Pharmacol. 30: 163-169, 1990.
26. Macri, J., and K. Adeli. Studies on intracellular translocation of apolipoprotein B in a permeabilized HepG2 system. J. Biol. Chem. 272: 7328-7337, 1997.
27. Markell, M. S., V. Armenti, G. Danovitch, and N. Sumrani. Hyperlipidemia and glucose intolerance in the post-renal transplant patient. J. Am. Soc. Nephrol. 4, Suppl. 8: S37-S47, 1994.
28. Molkentin, J. D., J. R. Lu, C. L. Antos, B. Markham, J. Richardson, J. Robbins, S. R. Grant, and E. N. Olson. A calcineurin-dependent transcriptional pathway for cardiac hypertrophy. Cell 93: 215-228, 1998.
29. Navasa, M., D. A. Gordon, N. Hariharan, H. Jamil, J. K. Shigenaga, A. Moser, W. Fiers, A. Pollock, C. Grunfeld, and K. R. Feingold. Regulation of microsomal triglyceride transfer protein mRNA expression by endotoxin and cytokines. J. Lipid Res. 39: 1220-1230, 1998.
30. Nooter, K., B. Meershoek, W. Spaans, P. Sonneveld, R. Oostrum, and J. Deurloo. Blood and tissue distribution of cyclosporin A after a single oral dose in the rat. Experientia 40: 559-561, 1984.
31. Princen, H. M., P. Meijer, B. G. Wolthers, R. J. Vonk, and F. Kuipers. Cyclosporin A blocks bile acid synthesis in cultured hepatocytes by specific inhibition of chenodeoxycholic acid synthesis. Biochem. J. 275: 501-505, 1991.
32. Rao, A., C. Luo, and P. G. Hogan. Transcription factors of the NFAT family: regulation and function. Annu. Rev. Immunol. 15: 707-747, 1997.
33. Rehberg, E. F., M. E. Samson-Bouma, B. Kienzle, L. Blinderman, H. Jamil, J. R. Wetterau, L. P. Aggerbeck, and D. A. Gordon. A novel abetalipoproteinemia genotype. Identification of a missense mutation in the 97-kDa subunit of the microsomal triglyceride transfer protein that prevents complex formation with protein disulfide isomerase. J. Biol. Chem. 271: 29945-29952, 1996.
34. Ruhlmann, A., and A. Nordheim. Effects of the immunosuppressive drugs CsA and FK506 on intracellular signalling and gene regulation. Immunobiology 198: 192-206, 1997.
35. Sakai, J., A. Nohturfft, D. Cheng, Y. K. Ho, M. S. Brown, and J. L. Goldstein. Identification of complexes between the COOH-terminal domains of sterol regulatory element-binding proteins (SREBPs) and SREBP cleavage-activating protein. J. Biol. Chem. 272: 20213-20221, 1997.
36. Shimano, H., J. D. Horton, R. E. Hammer, I. Shimomura, M. S. Brown, and J. L. Goldstein. Overproduction of cholesterol and fatty acids causes massive liver enlargement in transgenic mice expressing truncated SREBP-1a. J. Clin. Invest. 98: 1575-1584, 1996.
37. Sturrock, N. D., and A. D. Struthers. Hormonal and other mechanisms involved in the pathogenesis of cyclosporin-induced nephrotoxicity and hypertension in man. Clin. Sci. (Colch.) 86: 1-9, 1994.
38. Ueda, C. T., M. Lemaire, G. Gsell, P. Misslin, and K. Nussbaumer. Apparent dose-dependent oral absorption of cyclosporin A in rats. Biopharm. Drug Dispos. 5: 141-151, 1984.
39. Wang, X., R. Sato, M. S. Brown, X. Hua, and J. L. Goldstein. SREBP-1, a membrane-bound transcription factor released by sterol-regulated proteolysis. Cell 77: 53-62, 1994.
40. Wetterau, J. R., L. P. Aggerbeck, M. E. Bouma, C. Eisenberg, A. Munck, M. Hermier, J. Schmitz, G. Gay, D. J. Rader, and R. E. Gregg. Absence of microsomal triglyceride transfer protein in individuals with abetalipoproteinemia. Science 258: 999-1001, 1992.
41. Wetterau, J. R., K. A. Combs, L. R. McLean, S. N. Spinner, and L. P. Aggerbeck. Protein disulfide isomerase appears necessary to maintain the catalytically active structure of the microsomal triglyceride transfer protein. Biochemistry 30: 9728-9735, 1991.
42. Wetterau, J. R., K. A. Combs, S. N. Spinner, and B. J. Joiner. Protein disulfide isomerase is a component of the microsomal triglyceride transfer protein complex. J. Biol. Chem. 265: 9801-9807, 1990.
43. Winegar, D. A., J. A. Salisbury, S. S. Sundseth, and R. L. Hawke. Effects of cyclosporin on cholesterol 27-hydroxylation and LDL receptor activity in HepG2 cells. J. Lipid Res. 37: 179-191, 1996.